Understanding Fanconi Renotubular Syndrome 1 (FRTS1)
At a Glance
Fanconi Renotubular Syndrome 1 (FRTS1) is a rare inherited kidney disorder caused by a GATM gene change. The kidneys lose phosphate and other substances, which can cause rickets, poor growth, and kidney problems; treatment replaces losses and monitors health.
Receiving a diagnosis of Fanconi Renotubular Syndrome 1 (FRTS1) can feel like being handed a map to a place no one has ever heard of. If your local doctor seemed unfamiliar with the name, it is because FRTS1 is exceptionally rare and was only recently linked to its genetic cause [1][2]. It is normal to feel overwhelmed when the medical community is still learning about your child’s condition. This page is designed to help you understand what this diagnosis means, how it differs from other similarly named conditions, and what researchers currently know.
What is Fanconi Renotubular Syndrome 1?
FRTS1 is a genetic disorder that primarily affects the proximal tubules—the tiny “recycling centers” within the kidneys [1]. Normally, these tubules reclaim vital substances like phosphate, glucose, and amino acids from the filtered blood and put them back into the body. In FRTS1, a mutation in the GATM gene causes a protein to clump together inside the mitochondria (the energy-producing parts of the cell) of these tubule cells [1][3].
This clumping damages the cells, causing them to “leak” essential nutrients into the urine instead of keeping them in the body [1]. This leakage is known as renal Fanconi syndrome. Common substances lost in the urine include:
- Phosphate, which is critical for bone strength [4].
- Glucose (sugar), even when blood sugar levels are normal [1].
- Amino acids, the building blocks of proteins [5].
- Bicarbonate, which helps balance acid levels in the blood [1].
- Low-molecular-weight proteins, a key marker of tubule stress [6].
FRTS1 is Not Fanconi Anemia
One of the most common points of confusion for families is the name. Despite the similar name, Fanconi Renotubular Syndrome 1 is not the same as Fanconi Anemia [1][5].
- Fanconi Anemia is a disorder of DNA repair that primarily affects the bone marrow and increases cancer risk.
- FRTS1 primarily causes kidney, bone, and metabolic effects related to the GATM gene [1], though extra-renal findings and severity vary.
They are named after the same pediatrician (Guido Fanconi), but they affect the body in entirely different ways. If you are searching for information online, ensure you are looking for “GATM-associated Fanconi syndrome” or “Renotubular Syndrome” to avoid confusing these two conditions.
Typical Presentation and Childhood Impact
The most common way FRTS1 appears in childhood is through hypophosphatemic rickets [1][7]. Because the kidneys are leaking too much phosphate, the body does not have enough “glue” to harden the bones. This can lead to:
- Leg bowing or other skeletal changes [8].
- Slowed growth or short stature [2].
- Bone pain or muscle weakness [9].
In some children, these symptoms appear in infancy, while in others, they may be milder or appear later [1]. Because the symptoms can vary so much, even within the same family, doctors refer to this as phenotypic variability [2][9]. Adults may present with unexplained chronic kidney disease or bone softening (osteomalacia).
What Research Tells Us (and What It Doesn’t)
Because FRTS1 is so rare, there is still a great deal that researchers are working to understand.
| What Is Well-Understood | What Is Still Uncertain |
|---|---|
| Genetic Cause: FRTS1 is caused by mutations in the GATM gene [1]. | Incidence: We do not know exactly how many people have FRTS1; it is likely under-recognized [2]. |
| Mechanism: The damage happens because of protein clumping in kidney mitochondria [3]. | Long-term Outlook: Some reports show kidney function can decline over decades, while others show it staying stable into late adulthood [2][9]. |
| Inheritance: It is an autosomal dominant condition, meaning inheriting one pathogenic copy brings a high chance of clinical expression [3]. | Optimal Treatment: There is no proven protocol to halt the genetic process; doctors currently treat it by replacing what the kidneys leak [10]. |
Navigating the Emotional Impact
A rare disease diagnosis often brings a unique type of isolation. You may find yourself becoming the “expert” on your child’s condition because you have to explain it to every new nurse or therapist you meet [11].
The emotional weight of managing a chronic condition—balancing school, medications, and frequent blood tests—can lead to stress for both parents and children [12][13]. Seeking out specialized networks, such as the European Rare Kidney Disease Reference Network (ERKNet) or rare disease advocacy groups, can help connect you with specialists and other families who understand this journey [14][15]. You are not alone, even if the diagnosis is rare.
Management and Monitoring
While there is no cure yet for the underlying genetic mutation, the goal of care is to manage the losses and protect the bones and kidneys. This typically involves:
- Supplementation: Clinician-directed replacement of phosphate and vitamin D to treat or prevent rickets [8].
- Acid Balance: Using bicarbonate or citrate if the blood becomes too acidic [4].
- Regular Monitoring: Frequent blood and urine tests to check mineral levels and kidney function (eGFR) [2][16].
- Growth Tracking: Monitoring height and bone development closely during childhood [17].
Common questions in this guide
What is Fanconi Renotubular Syndrome 1, and what causes it?
Is FRTS1 the same as Fanconi anemia?
What symptoms can FRTS1 cause in children?
How is FRTS1 inherited?
How is FRTS1 treated and monitored?
Can FRTS1 worsen kidney function over time?
Get notified when new evidence is published on Fanconi renotubular syndrome 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Complex phenotype in Fanconi renotubular syndrome type 1: Hypophosphatemic rickets as the predominant presentation.
Li CY, Sun Y, Guo WC, et al.
Clinica chimica acta; international journal of clinical chemistry 2024; (561()):119812 doi:10.1016/j.cca.2024.119812.
PMID: 38876250 - 2
Genetic Screening of Patients With Inherited Fanconi Syndrome.
Inoki Y, Sakakibara N, Yamamoto A, et al.
Kidney international reports 2026; (11(7)):106576 doi:10.1016/j.ekir.2026.106576.
PMID: 42282999 - 3
Renal proteomic landscape of a patient with Fanconi renotubular syndrome carrying a novel GATM variant.
Lu F, Yang L, Qian S, et al.
Frontiers in physiology 2026; (17()):1921122 doi:10.3389/fphys.2026.1921122.
PMID: 42845598 - 4
Renal Tubular Acidosis.
Bagga A, Sinha A
Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.
PMID: 32591997 - 5
Rickets in proximal renal tubular acidosis: a case series of six distinct etiologies.
Singhania P, Dhar A, Deshpande A, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(9)):879-885 doi:10.1515/jpem-2023-0155.
PMID: 37434360 - 6
Proximal renal tubular acidosis with and without Fanconi syndrome.
Kashoor I, Batlle D
Kidney research and clinical practice 2019; (38(3)):267-281 doi:10.23876/j.krcp.19.056.
PMID: 31474092 - 7
Inherited Fanconi syndrome.
Albuquerque ALB, Dos Santos Borges R, Conegundes AF, et al.
World journal of pediatrics : WJP 2023; (19(7)):619-634 doi:10.1007/s12519-023-00685-y.
PMID: 36729281 - 8
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187 - 9
Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.
Ragate DC, Memon SS, Karlekar M, et al.
Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.
PMID: 38310177 - 10
Fanconi Syndrome.
Foreman JW
Pediatric clinics of North America 2019; (66(1)):159-167 doi:10.1016/j.pcl.2018.09.002.
PMID: 30454741 - 11
Genetic Testing in the Pediatric Nephrology Clinic: Understanding Families' Experiences.
Nevin SM, McLoone J, Wakefield CE, et al.
Journal of pediatric genetics 2022; (11(2)):117-125 doi:10.1055/s-0040-1721439.
PMID: 35769952 - 12
Addressing the psychosocial aspects of transition to adult care in patients with cystinosis.
Stabouli S, Sommer A, Kraft S, et al.
Pediatric nephrology (Berlin, Germany) 2024; (39(10)):2861-2874 doi:10.1007/s00467-024-06345-1.
PMID: 38517536 - 13
Qualitative Analysis of the Psychosocial Adaptation Process in Children with Chronic Kidney Disease: Toward Effective Support During Transition from Childhood to Adulthood.
Aoto H, Nakatani H, Kanayama S, et al.
Yonago acta medica 2018; (61(3)):166-174.
PMID: 30275747 - 14
[The European Rare Kidney Disease Reference Network].
Wlodkowski T, Haeberle S, Schaefer F
Innere Medizin (Heidelberg, Germany) 2024; (65(12)):1283-1292 doi:10.1007/s00108-024-01810-3.
PMID: 39538006 - 15
Changing Needs for Information and Support in an Online System for Parents of Children With Kidney Disease.
Pinsk M, Nicholas D
Canadian journal of kidney health and disease 2017; (4()):2054358117714999 doi:10.1177/2054358117714999.
PMID: 28717515 - 16
Refractory Rickets: Evaluation and Management.
Krishnamurthy S
Indian journal of pediatrics 2026; (93(6)):612-620 doi:10.1007/s12098-026-06032-z.
PMID: 41741919 - 17
Management of bone disease in cystinosis: Statement from an international conference.
Hohenfellner K, Rauch F, Ariceta G, et al.
Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.
PMID: 31177550
This page provides educational information about Fanconi Renotubular Syndrome 1 and does not replace medical advice. A kidney specialist and genetics team should interpret your child's results and tailor treatment and monitoring.